Quince Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Quince Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($13.44M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($16.05M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($15.03M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.49M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($27.73M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($11.15M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($5.35M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.89M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.25M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($7.92M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($16.56M) | Aug 3, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($21.64M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($21.71M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($21.75M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($23.09M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($21.51M) | Oct 29, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($17.61M) | Aug 6, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($17.18M) | May 6, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($9.86M) | Nov 12, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($9.06M) | Aug 14, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($13.43M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($10.43M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($14.86M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.86M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($28.19M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($11.22M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($6.09M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.58M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.96M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($7.62M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($16.26M) | Aug 3, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($21.86M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($21.68M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($21.78M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($23.31M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($21.91M) | Oct 29, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($18.27M) | Aug 6, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($17.86M) | May 6, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($10.57M) | Nov 12, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($9.58M) | Aug 14, 2020 |